SG11202011242SA - SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS - Google Patents

SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Info

Publication number
SG11202011242SA
SG11202011242SA SG11202011242SA SG11202011242SA SG11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA
Authority
SG
Singapore
Prior art keywords
rur20kd
related compositions
selective treg
treg stimulator
stimulator
Prior art date
Application number
SG11202011242SA
Inventor
Peter Benedict Kirk
John L Langowski
Jonathan Zalevsky
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of SG11202011242SA publication Critical patent/SG11202011242SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
SG11202011242SA 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS SG11202011242SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
SG11202011242SA true SG11202011242SA (en) 2020-12-30

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011242SA SG11202011242SA (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Country Status (19)

Country Link
US (1) US20210205413A1 (en)
EP (1) EP3796940A1 (en)
JP (2) JP7235772B2 (en)
KR (1) KR20210002577A (en)
CN (1) CN112399859A (en)
AU (2) AU2019274409B2 (en)
BR (1) BR112020021564A2 (en)
CA (1) CA3100204A1 (en)
CL (1) CL2020003008A1 (en)
CO (1) CO2020014510A2 (en)
CR (1) CR20200546A (en)
DO (1) DOP2020000212A (en)
EA (1) EA202092489A1 (en)
EC (1) ECSP20074392A (en)
JO (1) JOP20200290A1 (en)
PE (1) PE20211307A1 (en)
PH (1) PH12020551976A1 (en)
SG (1) SG11202011242SA (en)
WO (1) WO2019226538A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021140416A2 (en) * 2020-01-10 2021-07-15 Bright Peak Therapeutics Ag Modified il-2 polypeptides and uses thereof
WO2021143572A1 (en) * 2020-01-15 2021-07-22 天津键凯科技有限公司 Preparation method for pegylated biomolecules having controllable binding sites
CN113121670B (en) * 2020-01-15 2022-11-22 天津键凯科技有限公司 Disubstituted PEG (polyethylene glycol) interleukin 2 as well as preparation method and application thereof
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (en) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 Compound for the sequestration of undesirale anti-peg antibodies in a patient
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
WO2023114833A1 (en) 2021-12-14 2023-06-22 Eli Lilly And Company Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (en) 2001-06-20 2003-09-26 Oreal PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING AMIDE, SULFONAMIDE OR AROMATIC ACRYLONITRILE DERIVATIVES AND NOVEL AMIDE, SULFONAMIDE OR ACRYLONITRILE CARBAMATE DERIVATIVES
EP1626741A2 (en) 2003-05-23 2006-02-22 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
JP2014506116A (en) * 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Conjugate of IL-2 moiety and polymer
EP3443979B1 (en) * 2011-03-11 2020-05-27 Assistance Publique - Hôpitaux De Paris Il-2 dosage regimen for treating systemic lupus erythematosus
JP6911044B2 (en) * 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ Combination of glucocorticoid and polyethylene glycol-modified interleukin 2 for the treatment of respiratory diseases

Also Published As

Publication number Publication date
WO2019226538A1 (en) 2019-11-28
CA3100204A1 (en) 2019-11-28
AU2022246440A1 (en) 2022-11-03
AU2019274409B2 (en) 2022-07-14
BR112020021564A2 (en) 2021-03-02
KR20210002577A (en) 2021-01-08
AU2019274409A1 (en) 2020-11-12
CN112399859A (en) 2021-02-23
JP7235772B2 (en) 2023-03-08
DOP2020000212A (en) 2021-03-15
ECSP20074392A (en) 2021-03-31
US20210205413A1 (en) 2021-07-08
CR20200546A (en) 2021-05-18
PE20211307A1 (en) 2021-07-20
PH12020551976A1 (en) 2021-09-13
JP2021523922A (en) 2021-09-09
EA202092489A1 (en) 2021-03-16
EP3796940A1 (en) 2021-03-31
CL2020003008A1 (en) 2021-07-30
CO2020014510A2 (en) 2021-03-08
JOP20200290A1 (en) 2020-11-15
JP2023052053A (en) 2023-04-11

Similar Documents

Publication Publication Date Title
IL280134A (en) Anti-cd112r compositions and methods
SG11202008659TA (en) Cartyrin compositions and methods for use
SG11202011242SA (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
SG11202105626TA (en) Oligonucleotide compositions and methods thereof
ZA202004678B (en) Compositions comprising co-selected microbiota and methods for use thereof
GB201807325D0 (en) Compositions and methods
SG11202104448WA (en) Compositions and methods
IL279059A (en) Sporicidal methods and compositions
ZA202101362B (en) Compositions and methods for treating the eye
GB201815402D0 (en) Compositions and methods and uses relating thereto
GB2578519B (en) Compositions and methods and uses relating thereto
ZA202101342B (en) Compositions and methods for treating the eye
GB201810852D0 (en) Compositions, uses and methods
GB201804163D0 (en) Uses, compositions and methods
EP3773654C0 (en) Polypharmaceutical drug compositions and related methods
GB201817444D0 (en) Methods and compositions
ZA202101360B (en) Compositions and methods for treating the eye
ZA202101361B (en) Compositions and methods for treating the eye
ZA202004533B (en) Skin-brightening compositions and methods
EP3664773A4 (en) Hair treatment compositions and methods
IL290325A (en) Biopharmacuetical compositions and related methods
SG11202108262VA (en) Bacterialcidal methods and compositions
GB201819987D0 (en) Methods and compositions
GB201901413D0 (en) Compositions and their use
GB201703975D0 (en) Composition and methods